immunocore-logo-2018
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
May 29, 2024 07:00 ET | Immunocore Holdings plc
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma Following recent consultation with FDA,...
immunocore-logo-2018
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
February 28, 2024 07:34 ET | Immunocore Holdings Limited
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update KIMMTRAK (tebentafusp) net revenues of $67.6 million in Q4 2023 and $238.7 million in 2023;...
immunocore-logo-2018
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
January 05, 2024 07:00 ET | Immunocore Holdings Limited
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation Increasing commercial access to KIMMTRAK (tebentafusp-tebn)...
immunocore-logo-2018
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 07:00 ET | Immunocore Holdings Limited
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 January, 2024) Immunocore Holdings plc...
immunocore-logo-2018
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
November 07, 2023 07:00 ET | Immunocore Holdings Limited
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £49.7 million ($60.7 million) in Q3 2023, maintaining strong momentum in major...
immunocore-logo-2018
Immunocore to present at upcoming investor conferences
October 30, 2023 16:30 ET | Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 30 October 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a...
immunocore-logo-2018
Immunocore to present at upcoming investor conferences
September 01, 2023 16:00 ET | Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 September 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a...
immunocore-logo-2018
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 07:00 ET | Immunocore Holdings Limited
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £45.5 million ($57.8 million) in 2Q 2023; new launches in Italy, Austria,...
immunocore-logo-2018
Immunocore to report second quarter 2023 financial results and host call on August 10, 2023
August 03, 2023 08:00 ET | Immunocore Holdings Limited
Immunocore to report second quarter 2023 financial results and host call on August 10, 2023 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 August 2023) Immunocore...
immunocore-logo-2018
Immunocore to present at upcoming investor conferences
June 01, 2023 16:30 ET | Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 June 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a...